• linkedin
  • Increase Font
  • Sharebar

    Study: Fluocinolone acetonide 0.2 µg/day reduced DR progression

    Subanalysis comes from FAME trials

    Reviewed by Charles C. Wykoff, MD, PhD 

    Take-home message: Progression to proliferative diabetic retinopathy was reduced in patients treated with fluocinolone acetonide 0.2 µg/day. 

    Houston—Treatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.

    “The duration of continuous steroid exposure during the FAME trials provides a unique opportunity to address the clinical question of the effect of corticosteroids on the progression to PDR,” said Dr. Wykoff, Retina Consultants of Houston, Blanton Eye Institute and Houston Methodist Hospital, Houston.

    Treatment options for DME have expanded in the past decade, with four drugs now approved by the FDA for DME:

    •       ranibizumab (Lucentis, Genentech)
    •       aflibercept (Eylea, Regeneron)
    •       fluocinolone acetonide (Iluvien, Alimera Sciences)
    •       dexamethasone (Ozurdex, Allergan)

    “Through multiple phase III trials of DME in eyes with diabetic retinopathy, we’ve learned that VEGF inhibition can dramatically blunt the progression to PDR,” Dr. Wykoff said.

    Do corticosteroids have a similar impact?


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';